Advertisement


Aadel A. Chaudhuri, MD, PhD, on Personalizing Treatment for Oligometastatic Cancer

2021 ASTRO Annual Meeting

Advertisement

Aadel A. Chaudhuri, MD, PhD, of Washington University School of Medicine in St. Louis, discusses circulating tumor DNA, which has the potential to better personalize treatment for patients with oligometastatic cancer and help clinicians determine whether to offer systemic therapy alone or curative-intent local consolidative therapy.



Related Videos

Issues in Oncology

Daniel F. Hayes, MD, on Liquid Biopsies to Detect and Monitor Oligometastases

Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center, discusses whether liquid biopsies can provide insight into the challenge of curing metastatic breast and possibly other cancers, how oligometastases are similar to a primary cancer, and why some kinds of local therapy for widespread disease might improve survival and lead to a cure.

Prostate Cancer

Benjamin Movsas, MD, on Prostate Cancer: Patient-Reported Outcomes on Radiotherapy and Androgen Suppression

Benjamin Movsas, MD, of the Henry Ford Cancer Center, discusses results from the NRG Oncology/RTOG 0815 study, which explored dose-escalated radiotherapy alone or in combination with short-term hormonal therapy for patients with intermediate-risk prostate cancer. In addition to clinical outcomes, Dr. Movsas discusses patient-reported results in the study that may help patients make informed decisions when choosing between these treatment options (Abstract 4).

CNS Cancers

Erin Murphy, MD, on Low-Grade Glioma: Neurocognitive Function Following Treatment

Erin Murphy, MD, of Cleveland Clinic, discusses new data that show no apparent difference in cognitive performance up to 2 years post-treatment among adults with low-grade glioma who were treated with concurrent radiotherapy and temozolomide (Abstract 3258).

Breast Cancer
Lung Cancer
Issues in Oncology

Matthew Manning, MD, on Resolving Racial Disparities in the Treatment of Breast and Lung Cancers

Matthew Manning, MD, of Cone Health Cancer Center, discusses findings that showed changes to the way cancer care is delivered may help eliminate racial disparities in survival among patients with early-stage lung and breast cancers. Identifying and addressing obstacles that kept patients from finishing radiation treatments for cancer were associated with improved 5-year survival rates for all patients (Abstract 53).

Head and Neck Cancer

Shauna Campbell, DO, on Head and Neck Cancer: Toxicity Associated With Hypofractionated IMRT

Shauna Campbell, DO, of Cleveland Clinic, discusses results from her study that showed hypofractionated intensity-modulated radiation therapy (H-IMRT) in the definitive or postoperative treatment of head and neck cancers using ≥ 50 Gy in 20 fractions appears to be safe and well tolerated with modest toxicity. Dr. Campbell suggests that prospective studies comparing the safety and efficacy of H-IMRT with those of conventionally fractionated IMRT are warranted (Abstract 2313).

Advertisement

Advertisement




Advertisement